Targeting cannabinoid receptor 2 (CB2) limits collagen production—An in vitro study in a primary culture of human fibroblasts
Authors:
- 14 July 2021
- journal article
- research article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 36 (1) , 89-99
Abstract
Previous studies showed that cannabinoid 2 (CB2) receptor is involved in skin inflammation, fibrogenesis and re‐epithelialization in mice, indicating that this receptor may be implicated in wound healing. Thus, topical use of cannabinoids may have a role in local fibrotic and wound healing diseases such as scars or keloids. We investigate the effect of the CB2 selective receptor agonist (6aR,10aR)‐3‐(1,1‐Dimethylbutyl)‐6a,7,10,10a‐tetrahydro‐6,6,9‐trimethyl‐6H‐dibenzo[b,d]pyran (JWH133) and the CB2 selective receptor antagonist (6‐Iodo‐2‐methyl‐1‐[2‐(4‐morpholinyl)ethyl]‐1H‐indol‐3‐yl)(4‐methoxyphenyl)‐methanone (AM630), on primary cultures of human fibroblasts. Primary cultures of adult human fibroblasts were obtained from abdominal human skin samples. Fibroblasts pretreated with JWH133 and/or AM630 were stimulated with TGF‐β (10 ng/ml). Fibroblast activation into myofibroblasts was quantified by the expression of alpha‐smooth muscle actin (α‐SMA) using Immunocytochemistry and Western Blot assays. Collagen content was quantified with the Sirius red staining assay. Upon human fibroblasts stimulation with TGF‐β, a significant increase on α‐SMA and CB2 receptor expression was observed. In these cells, JWH133 decreased α‐SMA expression and collagen content. However, this effect was not observed in resting human fibroblasts. AM630 decreased α‐SMA expression and collagen content in both resting and activated fibroblasts. This effect was time‐ and concentration‐dependent with an IC50 value of 11 μM. The CB2 receptor appears to be involved in fibroblast repair during skin wound healing in humans, as TGF‐β increases CB2 receptor expression and JWH133 produces an anti‐fibrotic effect in human fibroblasts. AM630 also showed an anti‐fibrotic effect hypothesizing that other cannabinoid receptors, such as TRPV, may be involved in this response.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (PTDC/DTP‐FTO/1018/2014)
This publication has 42 references indexed in Scilit:
- Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neuronsNeuropharmacology, 2011
- The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin modelAnnals of the Rheumatic Diseases, 2011
- International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2Pharmacological Reviews, 2010
- Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosisArthritis & Rheumatism, 2010
- Targeting the Cannabinoid Pathway Limits the Development of Fibrosis and Autoimmunity in a Mouse Model of Systemic SclerosisThe American Journal of Pathology, 2010
- Cannabinoids as Novel Anti-Inflammatory DrugsFuture Medicinal Chemistry, 2009
- The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunitiesTrends in Pharmacological Sciences, 2009
- Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblastsRheumatology, 2009
- The cannabinoid system and its pharmacological manipulation – a review, with emphasis upon the uptake and hydrolysis of anandamideFundamental & Clinical Pharmacology, 2006
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006